ライフサイエンスコーパス: Roche

1 16S 454 FLX titanium series pyrosequencing (Roche).

2 imens by IDEIA PCE EIA (Dako) and Cobas PCR (Roche).

3 ed with the MagNA Pure LC extraction system (Roche).

4 ared with laboratory pVL assessment (TaqMan, Roche).

5 M was sequenced (RNA-Seq) using GS FLX+ (454/Roche).

6 h Network, the Medical Research Council, and Roche.

7 ma Research Trust, Lymphoma Association, and Roche.

8 t protease inhibitor (saquinavir, Hoffman La-Roche, 1995) and two decades since the approval of the f

9 nomes exon pilot project generated using the Roche 454 and Illumina sequencing platforms, and were ab

10 Users can turn a collection of reads (from Roche 454 chemistry) or assembled contigs (from any sequ

11 SR in comparison to Roche gsAssembler on two Roche 454 GS FLX runs.

12 us strain genome sequencing was performed on Roche 454 GS FLX Titanium, then AB SOLiD instruments.

13 umina (Genome Analyzer, HiSeq, MiSeq, .etc), Roche 454 GS System, Applied Biosystems SOLiD System, He

14 ected to high-throughput pyrosequencing on a Roche 454 GS-FLX platform.

15 Here we used Roche 454 next-generation pyrosequencing of sedimentary

16 We used capillary electrophoresis and Roche 454 pyrosequencing to determine the number of repe

17 Culture-independent high-density Roche 454 pyrosequencing was used to survey the distal g

18 ria, as compared with standard single-region Roche 454 Pyrosequencing.

19 Roche 454 sequencing data were assembled into c. 22,000

20 Using Roche 454 sequencing of reverse transcription polymerase

21 rom selected multiplex T1D families, we used Roche 454 sequencing with Conexio Genomics ASSIGN ATF 45

22 n sequencing platforms (SOLiD, Illumina, and Roche 454).

23 s PGM and Proton, Pacific Biosciences RS and Roche 454).

24 resulting sample with both Illumina GAII and Roche 454, and obtained data with equally high specifici

25 DNA sequencing data from the Roche 454, Illumina/Solexa, and ABI SOLiD platforms typi

26 The amplicons were sequenced by Roche 454, the genomes assembled by de novo assembly, an

27 m detection, and apply them to data from the Roche (454) Genome Sequencer 20.

28 Here, we have used Roche-454 16S rRNA gene pyrosequencing to longitudinally

29 bidopsis thaliana), is being assembled using Roche-454 sequencing.

30 Yoka poxvirus genome using a combination of Roche/454 and Illumina next-generation sequencing techno

31 inGAP can be applied to the mapping of both Roche/454 and Illumina reads with no restriction of read

32 detection assay is made compatible with the Roche/454 Genome Sequencer FLX Titanium next-generation

33 Using Roche/454 GS FLX instrument, we acquired 7.6 million seq

34 using the long-read pyrosequencing platform (Roche/454 GS FLX Titanium) in high coverage.

35 ients infected with subtype 1a and performed Roche/454 pyrosequencing across the coding region.

36 I typing was performed on cellular RNA using Roche/454 pyrosequencing.

37 th high sensitivity and specificity, in both Roche/454 sequencing of individuals and deep Illumina/So

38 Roche/454 sequencing of the adult transcriptome produced

39 We compare sequencing platforms from Roche/454(GS FLX), Illumina/HiSeq (HiSeq 2000), and Life

40 IV reverse transcriptase (RT) was performed (Roche/454), and the sequences were screened for nucleosi

41 oughput and relatively short read lengths of Roche/454, Illumina/Solexa, and other platforms have spu

42 Chiral Roche aldehyde is obtained with 97% ee from the hydrofor

43 y (hs) cTn assays (hs-cTnI, Abbott; hs-cTnT, Roche) among 2300 consecutive patients with suspected AM

44 .3% for the Roche Cobas assay, 94.5% for the Roche Amplicor assay, 93.0% for the Biocentric assay, an

45 comparing the performances of ddPCR and the Roche Amplicor CT/NG test.

46 y two commercially available RNA assays, the Roche Amplicor HIV-1 Monitor and the bioMerieux NucliSen

47 In the Roche Amplicor HIV-1 Monitor Test, the ratio of the opti

48 These assays were compared to the Roche Amplicor HIV-1 Monitor Test, v1.5, using panels of

49 -1 subtype detection, and correlation to the Roche Amplicor HIV-1 monitor test, version 1.5 (Amplicor

50 y (LCx), Bayer Versant HIV-1 RNA 3.0 (bDNA), Roche AMPLICOR HIV-1 MONITOR v1.5 (Monitor v1.5), and bi

51 The Roche Amplicor HIV-1 Test requires that whole blood be p

52 [RT-PCR]), Roche TaqMan RUO (Roche RT-PCR), Roche Amplicor Monitor HCV 2.0 (Roche Monitor), and Baye

53 etectable serum hepatitis B virus (HBV) DNA (Roche Amplicor Monitor polymerase chain reaction [PCR] a

54 ma viral loads using the Abbott test and the Roche Amplicor Monitor test showed a mean difference of

55 three FDA-approved platforms: UltraSensitive Roche Amplicor Monitor, v1.5 (Monitor), the Abbott RealT

56 s tested individually and in pools using the Roche Amplicor PCR for C. trachomatis and N. gonorrhoeae

57 obeTec SDA, Gen-Probe Aptima Combo2 TMA, and Roche Amplicor PCR) for detection of C. trachomatis and

58 nson ProbeTec, Gen-Probe Aptima Combo 2, and Roche Amplicor tests to detect Chlamydia trachomatis and

59 al conditions, viral RNA was detected by the Roche Amplicor UltraSensitive assay in whole-milk, skim

60 virus type 1 (HIV-1) plasma RNA levels using Roche AMPLICOR version 1.5 (HIV RNA) is an integral part

61 tion [PCR] results for C. trachomatis DNA by Roche Amplicor) and 25 true-negative specimens (direct o

62 Concordance with the Roche Amplicor, BDProbeTec ET, and Gen-Probe APTIMA Comb

63 ted a sensitivity of 100% (46/46), while the Roche analyte-specific reagents (ASR) and LDT showed sen

64 a laboratory-developed test (LC CMV) (using Roche analyte-specific reagents [ASR] on the LightCycler

65 nd ribavirin had HCV RNA <LLOQ at EOT by the Roche and Abbott assays, but only 38 achieved SVR12 (PPV

66 solid form screens conducted at Hoffmann-La Roche and Eli Lilly and Company over the course of 8+ an

67 th; with drug supply provided by Hoffmann-La Roche and Genentech.

68 gle-nucleotide polymorphisms (SNPs) from the Roche and Genomic Institute of the Novartis Research Fou

69 RESTO has been tested on data generated from Roche and Illumina platforms.

70 hilst at least one in two compounds from the Roche and Lilly set display polymorphism with a higher e

71 as found in VitaCyte product followed by the Roche and Serva/Nordmark products.

72 Roche and the National Institute for Health Research thr

73 injury and apoptosis detectable with TUNEL (Roche) and dual annexin V and propidium iodide staining.

74 ining data generated from 454 Life Sciences (Roche) and Illumina (formerly known as Solexa sequencing

75 Using 454 Life Sciences (Roche) and Illumina sequencing (formerly Solexa sequenci

76 was accomplished using a combination of 454 (Roche) and Illumina sequencing and community-based fundi

77 e sequences for 19 Typhi isolates using 454 (Roche) and Solexa (Illumina) technologies.

78 iiV Healthcare, Merck, Pfizer, F Hoffmann-La Roche, and Janssen Pharmaceuticals.

79 Ingelheim, Janssen, Merck, ViiV Healthcare, Roche, and Monogram Biosciences (LabCorp).

80 real-time PCR method using the LightCycler (Roche Applied Science, Indianapolis, IN) was compared to

81 ssing with the MagNA Pure LC instrument (MP; Roche Applied Science, Indianapolis, IN) were evaluated

82 NA to develop a rapid real-time LightCycler (Roche Applied Science, Indianapolis, Ind.) PCR assay for

83 instrument and total nucleic acid reagents (Roche Applied Science, Indianapolis, Ind.) to extract hu

84 e PCR method, the LightCycler Strep-A assay (Roche Applied Science, Indianapolis, Ind.), to those of

85 cessing by the MagNA Pure LC instrument (MP; Roche Applied Science, Indianapolis, Ind.).

86 xtraction with the MagNA Pure LC instrument (Roche Applied Science, Indianapolis, Ind.).

87 A screening assay for real-time LightCycler (Roche Applied Science, Mannheim, Germany) PCR identifica

88 48 instrument (Qiagen, Inc.) and MagNA Pure (Roche Applied Sciences) methods, to two manual methods,

89 The Roche ASR in combination with the High Pure system (Roch

90 Roche ASR-HP underestimated HCV RNA for genotypes 3 and

91 SR in combination with the High Pure system (Roche ASR-HP) showed a sensitivity of 1.4 log(10) IU/ml

92 on (R(2) = 0.79) and agreement were poor for Roche ASR-HP, with bias relative to concentration and ge

93 trated increased sensitivity compared to the Roche ASR.

94 -9451, 100% (59/59) had HCV RNA <LLOQ by the Roche assay and 1 relapsed (PPV, 98%).

95 the Abbot assay was more sensitive than the Roche assay for both C. trachomatis and N. gonorrhoeae.

96 assay and those detected by the Siemens and Roche assays (92.0% and 88% correlation coefficient of t

97 near and correlate well with the established Roche assays used in clinical practice.

98 Basel, Switzerland) and daclizumab (Zenapax; Roche, Basel, Switzerland) combined (relative risk, 0.54

99 h factor (VEGF) agent ranibizumab (Lucentis; Roche, Basel, Switzerland) compared with ranibizumab mon

100 ion, chlorination, and amination of the homo-Roche building blocks was performed to demonstrate that

101 says and 0.99 (95% CI, 0.96 to 1.00) for the Roche CAP/CTM Qual assay.

102 al [CI], 0.95 to 1.00) for the AmpliSens and Roche CAP/CTM Qual assays and 0.96 (95% CI, 0.90 to 0.98

103 mmended threshold of >1,000 copies/ml on the Roche CAP/CTM system.

104 tem cytomegalovirus (CMV) DNA (version 2.0), Roche CMV UL54 analyte-specific reagent, and QIAGEN Real

105 n susceptibility using residual DNA from the Roche Cobas 4800 CT/NG assay.

106 mydia trachomatis and Neisseria gonorrhoeae (Roche cobas 4800), a fully automated system, was compare

107 asured via indirect potentiometry, using the Roche Cobas 8000 routine chemistry analyzer.

108 Roche COBAS Amplicor and Bayer VERSANT HCV RNA qualitati

109 Results were compared to those of the Roche Cobas Amplicor CT/NG assay.

110 polymerase chain reaction (PCR)-based assay (Roche COBAS Amplicor HCV Test, v.

111 at the amplicon generated by the widely used Roche COBAS Amplicor Hepatitis C Virus Test, version 2.0

112 The Roche COBAS AMPLICOR human immunodeficiency virus type 1

113 DNA strand displacement assay (SDA), and the Roche Cobas Amplicor PCR was defined by using a rotating

114 me PCR assay by comparison with the existing Roche COBAS AmpliPrep/AMPLICOR MONITOR conventional PCR

115 ed with the AmpliSens DNA-HIV-FRT assay, the Roche COBAS AmpliPrep/COBAS TaqMan (CAP/CTM) HIV-1 Qual

116 We evaluated the FDA-approved Roche Cobas AmpliPrep/Cobas TaqMan (CAP/CTM) HIV-1 viral

117 Although Roche COBAS Ampliprep/COBAS TaqMan (CAP/CTM) systems are

118 The Roche Cobas AmpliPrep/Cobas TaqMan CMV test (Cobas CMV)

119 e assessed: the Abbott RealTime HBV IUO, the Roche Cobas AmpliPrep/Cobas TaqMan HBV test, the Roche C

120 Two new FDA-approved assays, the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test (RT) and t

121 Compared to the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test, the new S

122 results were compared with results from the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 test, v2.0.

123 tima assay was also compared to those of the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 v.2 (CAP/CTM) a

124 mated real-time HIV-1 viral load assays, the Roche Cobas AmpliPrep/Cobas TaqMan test and the Abbott R

125 ots (DPS) with a commonly used VL assay, the Roche Cobas Ampliprep/Cobas TaqMan V.2.0 (CAP/CTM).

126 fied inefficiently with gSCA compared to the Roche Cobas Ampliprep/TaqMan 2.0, whereas all 10 samples

127 iagnostic Medical Devices Directive-approved Roche COBAS AmpliPrep/TaqMan96 real-time PCR assay by co

128 re 96.6% for the Abbott assay, 96.3% for the Roche Cobas assay, 94.5% for the Roche Amplicor assay, 9

129 inflammatory biomarkers were measured using Roche cobas c702 and Meso Scale Discovery V-Plex Plus: h

130 The sensitivity of the Roche COBAS Monitor v.2.0 test was slightly better than

131 point was proportion with HBV DNA <69 IU/mL (Roche COBAS Taqman assay; Roche Molecular Systems, Inc,

132 e Cobas AmpliPrep/Cobas TaqMan HBV test, the Roche Cobas TaqMan HBV test with HighPure system, and th

133 urements of HCV RNA were performed using the Roche COBAS TaqMan HCV test and the Abbott RealTime HCV

134 The Roche COBAS TaqMan HCV test for research use only (RUO)

135 We evaluated the Abbott RealTime (ART) and Roche Cobas TaqMan Hepatitis C virus (HCV) viral load as

136 st) and compared results with those of LABT (Roche COBAS TaqMan HIV-1 Qualitative test) with respect

137 he use of an analyte-specific reagent (ASR) (Roche COBAS TaqMan48 [CTM48] HCV) after manual and autom

138 ulvovaginal-swab and urine specimens by PCR (Roche Cobas) or strand displacement amplification (SDA;

139 tibodies from different vendors (Vector, BD, Roche, Dako, Novocastra, and Accurate) and DNA denaturat

140 24 weeks (polymerase chain reaction, TaqMan, Roche; detection limit 10 IU/mL).

141 NA was quantified by using Amplicor Monitor (Roche Diagnostic Systems, Inc, Branchburg, NJ) from 275

142 -Probe Inc.), the Amplicor CT/NG Assay (PCR; Roche Diagnostics Corp.), or the BD ProbeTec ET System C

143 itative and quantitative AMPLICOR HCV tests (Roche Diagnostics Corp., Indianapolis, Ind.).

144 n instruments, the MagNA Pure LC instrument (Roche Diagnostics Corporation) and the lower-capacity Ma

145 ower-capacity MagNA Pure Compact instrument (Roche Diagnostics Corporation).

146 , the LightCycler vanA/vanB detection assay (Roche Diagnostics Corporation, Indianapolis, Ind.) to th

147 ghtCycler Strep B analyte-specific reagents (Roche Diagnostics Corporation, Indianapolis, Ind.), were

148 o 36 h after PCI with the Multiplate device (Roche Diagnostics GmbH, Mannheim, Germany).

149 or Chlamydia trachomatis by using COBAS PCR (Roche Diagnostics) and ligase chain reaction LCR (Abbott

150 d was extracted using the MagNA Pure system (Roche Diagnostics) and subsequently tested by each PCR m

151 tion capacity was documented by LightCycler (Roche Diagnostics) measurements of virion-associated hep

152 eared rapid (<20 min) PCR assay (Cobas Liat; Roche Diagnostics) to our routine influenza A and B real

153 the Linear Array HPV genotyping assay (LA) (Roche Diagnostics), INNO-LiPA HPV Genotyping Extra (LiPA

154 tics of the COBAS Amplicor HBV Monitor test (Roche Diagnostics), which measures hepatitis B virus (HB

155 energy transfer probes and the LightCycler (Roche Diagnostics), which will detect the presence of th

156 eic acid using the MagNA Pure LC instrument (Roche Diagnostics).

157 standard troponin T and testing for hs-cTnT (Roche Diagnostics, Basel, Switzerland) at presentation.

158 The Amplicor HIV-1 DNA PCR assay (Roche Diagnostics, Branchburg, NJ) requires 500 microl o

159 were sequenced with the 454GS FLX Titanium (Roche Diagnostics, Indianapolis, IN) and GAIIx (Illumina

160 ydia trachomatis and N. gonorrhoeae (CT/NG) (Roche Diagnostics, Indianapolis, IN) followed by confirm

161 ed to the TaqMan HCV load ASR assay (TaqMan; Roche Diagnostics, Indianapolis, IN) that targets the 5'

162 al-time PCR analyte-specific reagents (ASR) (Roche Diagnostics, Indianapolis, IN) were also tested by

163 agen, Gaithersburg, MD), the cobas HPV test (Roche Diagnostics, Indianapolis, IN), and the APTIMA HPV

164 ysis probes using the LightCycler platforms (Roche Diagnostics, Indianapolis, IN).

165 he AMPLICOR HIV-1 MONITOR test, version 1.5 (Roche Diagnostics, Indianapolis, Ind.).

166 using the LINEAR ARRAY HPV Genotyping Test (Roche Diagnostics, Indianapolis, Indiana), which detects

167 as recognized by the Elecsys NTproBNP assay (Roche Diagnostics, Indianapolis, Indiana).

168 cer Association, Lance Armstrong Foundation, Roche Diagnostics, Pfizer, and Novartis.

169 BMS, Pfizer, Boehringer Ingelheim, Roche Diagnostics.

170 hs-cTn was measured with 3 assays (hs-cTnT, Roche Diagnostics; hs-cTnI, Beckman-Coulter; hs-cTnI Sie

171 d B viruses (Alere i [Alere] and cobas Liat [Roche Diagnostics]) with the influenza A and B virus tes

172 otherapeutics, stimulated by the Hoffmann-La Roche discovery that Nutlin-3 can restore apoptosis in c

173 s-report) or standard reporting (std-report; Roche Elecys).

174 n be manipulated to give optically pure homo-Roche ester chirons.

175 Roche ester derivatives were converted to trisubstituted

176 ar sequence) from commercially available (R)-Roche ester in >10% overall yields.

177 ic hydrogenation routes to homologues of The Roche ester tend to be restricted to hydrogenations of i

178 es in a single run of the 454 Life Sciences (Roche) FLX sequencer.

179 F Hoffmann-La Roche-Genentech and the Breast Cancer Research Foundatio

180 as those produced by the 454 Life Sciences (Roche) Genome Sequencer, and can scale to large data set

181 Hoffmann-La Roche global drug safety database for the time frame 31

182 ronchial biopsy specimens was sequenced with Roche GS FLX.

183 16S ribosomal RNA was sequenced with Roche GS-FLX (Genome Sequencer-FLX) pyrosequencing.

184 bled and reconstructed from whole genome 454 Roche GS-FLX and Illumina shotgun sequences.

185 rate the utility of HighSSR in comparison to Roche gsAssembler on two Roche 454 GS FLX runs.

186 ose recovered with the manual methods (i.e., Roche High Pure kit [133,900 CFU/ml], QIAamp DNA Mini ki

187 QIAamp DNA Mini kit recovered more than the Roche High Pure kit.

188 ncordance in HCV RNA assessments between the Roche High Pure System/Cobas TaqMan and Abbott RealTime

189 sults from samples tested prospectively with Roche High Pure TaqMan HCV 2.0 test (HPS) were compared

190 Human papillomavirus (HPV) was detected by Roche HPV Linear Array at enrollment, and at 6, 12, and

191 The Roche HPV Linear Array Genotype Test detected high-risk

192 ginal swabs were tested for high-risk HPV by Roche HPV Linear Array.

193 rcumcision trial in Rakai, Uganda, using the Roche HPV Linear Array.

194 ncing technologies (e.g., 454 Life Sciences [Roche], Illumina sequencing [formerly Solexa sequencing]

195 Founded by Roche in 1968, inaugurated in 1971, and closed in 2000,

196 In this article, we present a Roche in-house effort of screening 746 structurally dive

197 sured using an Accuchek() active glucometer (Roche Inc.).

198 ive ocular swabs was investigated (Amplicor; Roche, Indianapolis, IN).

199 National Institutes of Health, Genentech, Roche Laboratories, Lilly Research Laboratories, and Pre

200 Quantitative PCR (qPCR) (Roche Light Cycler 480) and ddPCR (Bio-Rad QX100 droplet

201 erence laboratories using two platforms, the Roche LightCycler 480 system and the Applied Biosystems

202 able solely by melt curve analysis using the Roche LightCycler HSV 1/2 analyte-specific reagent real-

203 We compared the performance of the new Roche LightCycler MRSA advanced test to that of the BD G

204 e and have recently been commercialized (eg, Roche LightCycler SeptiFast and T2 Biosystems T2Candida)

205 We evaluated the Roche LightCycler Staphylococcus M(GRADE) kits to differ

206 lder than Phobos' current orbit inside Mars' Roche limit.

207 f HC2-positive results were confirmed by the Roche line blot assay, compared to 77.2% of those at an

208 anal samples, against the reference standard Roche Linear Array (LA).

209 rcumcision trial in Rakai, Uganda, using the Roche Linear Array assay, which detects 37 HPV genotypes

210 s, and HPV genotypes were detected using the Roche Linear Array assay.

211 es, using a polymerase chain reaction assay (Roche Linear Array genotyping assay).

212 ce of L1 sequences using two versions of the Roche Linear Array genotyping assay.

213 and the widely used, commercially available Roche Linear Array genotyping PCR assay.

214 e compared the cobas HPV test (cobas) to the Roche Linear Array HPV genotyping assay (LA) and cytolog

215 A widely used genotyping assay is the Roche Linear Array HPV genotyping test (LA).

216 ere evaluated for 37 HPV genotypes using the Roche LINEAR ARRAY HPV Genotyping Test (Roche Molecular

217 for 36 HPV genotypes was performed using the Roche Linear Array HPV genotyping test.

218 For detection of HPV types, a Roche Linear Array test was performed.

219 cervical samples for HPV DNA detection using Roche Linear Array were collected semiannually for two y

220 ected penile swab sample for HPV genotyping (Roche Linear Array) and completed a demographic and risk

221 9 and PGMY11 L1 primer pools and by use of a Roche linear array.

222 Genital HPV genotypes were detected using Roche Linear Array.

223 Hoffmann-La Roche Ltd, Basel, Switzerland) versus ranibizumab (Lucen

224 Hoffmann-La Roche Ltd, Genentech, Inc.

225 rawn overview map of metabolism based on the Roche map satisfies (ii) and comes close to satisfying (

226 The 454 GS Junior (Roche), MiSeq (Illumina) and Ion Torrent PGM (Life Techn

227 The COBAS TaqMan HCV Test (TaqMan HCV; Roche Molecular Systems Inc., Branchburg, N.J.) for hepa

228 ated hrHPV tests, the cobas HPV test (cobas, Roche Molecular Systems) and Hybrid Capture 2 (hc2, Qiag

229 ) performed on the COBAS TaqMan 48 Analyzer (Roche Molecular Systems) currently relies on a manual sa

230 The linear array HPV genotyping test (Roche Molecular Systems) was used as a reference method

231 s C virus test, version 2.0 (COBAS AMPLICOR; Roche Molecular Systems), with TaqMan HCV detecting two

232 MPLICOR Hepatitis C Virus Test, version 2.0 (Roche Molecular Systems, Branchburg, N.J.) following man

233 ratories, Abbott Park, Ill.]; PCR [Amplicor; Roche Molecular Systems, Branchburg, N.J.]; and transcri

234 kinson Co., Sparks, MD), and Amplicor (PCR) (Roche Molecular Systems, Branchburg, NJ).

235 HBV DNA <69 IU/mL (Roche COBAS Taqman assay; Roche Molecular Systems, Inc, Pleasanton, CA).

236 TaqMan is a registered trademark of Roche Molecular Systems, Inc.

237 .), and COBAS TaqMan (COBAS TaqMan HCV Test; Roche Molecular Systems, Inc.) assays.

238 MPLICOR Hepatitis C Virus Test, version 2.0; Roche Molecular Systems, Inc.), and COBAS TaqMan (COBAS

239 B virus (HBV) analyte-specific reagent (ASR; Roche Molecular Systems, Inc., Branchburg, NJ) is design

240 OBAS AMPLICOR HCV MONITOR Test, version 2.0; Roche Molecular Systems, Inc., Branchburg, NJ), COBAS AM

241 Corp., Gaithersburg, MD), Linear Array (LA; Roche Molecular Systems, Pleasanton, CA), and Amplicor (

242 ular Systems, Pleasanton, CA), and Amplicor (Roche Molecular Systems, Pleasanton, CA).

243 the Roche LINEAR ARRAY HPV Genotyping Test (Roche Molecular Systems, Pleasanton, California), and fa

244 ens were determined using RealTime HIV-1 and Roche Monitor (v1.5).

245 Roche Monitor and Bayer bDNA detected 27 out of 28 and 1

246 The cost for the Roche Monitor assay kit can be reduced 50% by using only

247 for acute HIV infection) was compared with a Roche Monitor HIV RNA polymerase chain reaction assay.

248 ll correlated well with the results from the Roche Monitor Test (r = 0.83 to 0.96, r = 0.84 to 0.99,

249 che RT-PCR), Roche Amplicor Monitor HCV 2.0 (Roche Monitor), and Bayer VERSANT HCV RNA 3.0 (Bayer bDN

250 After resolving all Roche N. gonorrhoeae-positive results with two additiona

251 reaction assay and hybridization to a custom Roche NimbleGen promoter array.

252 a method for whole-exome sequencing coupling Roche/NimbleGen whole exome arrays to the Illumina DNA s

253 -32) and 2 commercial assays (Triage BNP and Roche NT-proBNP).

254 mmercially available critical care analyzer (Roche OPTI CCA) with precision better than +/- 1 mM (1 S

255 ew potassium sensor is currently used in the Roche OPTI CCA, a commercially available whole blood ana

256 swab specimens and equivalent to that of the Roche PCR for the detection of C. trachomatis with cervi

257 homatis and Neisseria gonorrhoeae testing by Roche PCR.

258 nt testing were both found to be positive by Roche PCR.

259 Roche Pharma AG, Mundipharma, German Federal Ministry of

260 irolimus or mycophenolate mofetil [CellCept, Roche Pharmaceutical, Nutley, NJ]).

261 erification process between the end user and Roche Pharmaceuticals, and mandatory destruction of empt

262 oup, under the sponsorship of Genentech Inc, Roche Pharmaceuticals, and OSI Pharmaceuticals, Inc, was

263 prednisone, mycophenolate mofetil (CellCept, Roche Pharmaceuticals, Basel, Switzerland), and cyclospo

264 rial genes from pooled samples using the 454/Roche platform.

265 scopy: the Hybrid Capture 2 (Qiagen), Cobas (Roche), PreTect HPV-Proofer (NorChip), Aptima HPV (Gen-P

266 Roche Products Ltd (educational grant), supported by Nat

267 meras using a nSSU data set derived from 454 Roche pyrosequencing of replicated, large control pools

268 udinal and cross-sectional samples using 454/Roche pyrosequencing, in total analyzing 174,185 sequenc

269 ethods were prospectively employed to impact Roche research projects, with the aim of highlighting th

270 Discrepant results were tested using the Roche reverse line blot (RLB) or Linear Array (LA) assay

271 ent with clinician-obtained brushes when the Roche Reverse Line Blot Assay (RLBA) was used (for swabs

272 HPV types were determined by the Roche Reverse Linear Array HPV genotyping assay.

273 The Roche RT-PCR assay gave mean viral load values that were

274 the mean viral load value obtained with the Roche RT-PCR assay was, on average, 0.15 log10 lower tha

275 nsitivity and linear range of the Abbott and Roche RT-PCR assays enable them to be used for HCV diagn

276 tested in the Bayer bDNA, Abbott RT-PCR, and Roche RT-PCR assays.

277 Abbott RT-PCR and Roche RT-PCR detected all 28 replicates with a concentra

278 anscription-PCR [RT-PCR]), Roche TaqMan RUO (Roche RT-PCR), Roche Amplicor Monitor HCV 2.0 (Roche Mon

279 Good correlation was obtained for the Roche RUO-MPLC and Abbott ASR-Q (R(2) = 0.84 and R(2) =

280 Our study demonstrates that Roche RUO-MPLC and Abbott ASR-Q provided acceptable resu

281 s processed on the MagNA Pure LC instrument (Roche RUO-MPLC) and Abbott analyte-specific reagents (AS

282 national units (IU) of IFN-alpha (Roferon-A; Roche s.p.a., Milano, Italy) subconjunctivally inside th

283 ogies such as Illumina's Solexa platform and Roche's 454 approach provide new avenues for investigati

284 ate performance on control data sequenced on Roche's 454 platform, and compare the results to the mos

285 led proportions were shotgun-sequenced using Roche's 454 sequencing platform.

286 ercial next-generation sequencing platforms: Roche's 454, Illumina's Solexa and Applied Biosystems' S

287 Collagenase from Roche, Serva/Nordmark (Uetersen, Germany), and VitaCyte

288 We included all published and unpublished Roche-sponsored randomised placebo-controlled, double-bl

289 orm and compared the results to those of the Roche TaqMan Analyte-Specific Reagent (TaqMan) and Bayer

290 1 test on the m2000 system (Abbott), and the Roche TaqMan HIV-1 test, v2.0 (TaqMan).

291 (Abbott reverse transcription-PCR [RT-PCR]), Roche TaqMan RUO (Roche RT-PCR), Roche Amplicor Monitor

292 VL was measured by Roche TaqMan.

293 apid virologic response (mRVR; VL <25 IU/mL [Roche TaqMan] at week 4 and undetectable at weeks 8 to 2

294 to 98.3%), respectively, compared to to the Roche test.

295 The finding by scientists at Hoffmann-La Roche that cis-imidazolines could disrupt the protein-pr

296 The sensitivities of the version 1.5 and 1.0 Roche UltraSensitive AMPLICOR HIV-1 MONITOR tests were c

297 or diluted using the Amplicor HIV-1 DNA PCR (Roche), version 1.5.

298 ded sequencing using the GS20 Sequencer (454/Roche), we found that over 99.8% of obtained sequences c

299 ive blood donation samples identified by the Roche WNV NAT.

300 To make this approach feasible, Roche would have to provide additional lysis buffer and